EUCTR2017-004260-36-ES进行中（未招募）1 期
Phase II multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with unresectable or metastatic urothelial carcinoma (UC) who have not received prior systemic therapy and who are ineligible to receive cisplatin-based therapy - Avelumab plus carboplatin-gemcitabine in UC
Associació Per a la Recerca Oncològica (APRO)0 个研究点目标入组 80 人开始时间: 2017年12月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1) The patient has given written informed consent stating that he or she understands the purpose of the study and the procedures involved and agrees to participate in the study.
- •2) The patient has histologically confirmed unresectable UC (T4b, any N; or any T, N2-3) or metastatic (M1, Stage IV) UC of the urinary tract, including renal pelvis, ureters, urinary bladder, and urethra
- •3) No prior systemic therapy for inoperable locally advanced or metastatic UC. For patients who received prior adjuvant/neoadjuvant chemotherapy or chemo radiation for UC, a treatment-free interval >12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment naive in the metastatic setting.
- •4) Ineligible (unfit”) for cisplatin-based chemotherapy as defined by any one of the following criteria:
- •a) Impaired renal function (GFR <60 mL/min)
- •b) ECOG performance status of 2
- •c) Grade =2 hearing loss (measured by audiometry) or =25 dB at two contiguous frequencies
- •d) Grade =2 peripheral neuropathy
- •* Criteria 4a and b are mutually exclusive: those patients with ECOG 2 won’t be allowed to have an impaired renal function. For rest of the criteria, several of them may coexist.
- •5) The patient has at least one measurable tumour lesion (measurable disease, as defined by the RECIST criteria v1.1). If all sites of measurable disease have been irradiated, one site must have demonstrated growth after irradiation.
- •6) Age =18 years.
- •7) ECOG PS 0-2.
- •8) Life expectancy of at least 12 weeks.
- •9) Adequate hematologic, hepatic, and renal function, defined by:
- •a) Platelet count =100 x10^9/L.
- •b) Hemoglobin = 9 g/dL (may have been transfused).
- •c) Absolute neutrophil count (ANC) =1.5x10^9/L.
- •d) Serum creatinine =1.5 times the upper limit of normality (ULN). If creatinine 1.0-1.5 xULN, creatinine clearance will be calculated according to Chronic Kidney Disease Epidemiology group (CKD-EPI) formula and patients with creatinine clearance <30 mL/min should be excluded.
- •NOTE: The CKD-EPI formula for creatinine clearance is as follows:
- •GFR = 141 x min(Scr/?,1)^a x max(Scr/?,1)^-1.209 x 0.993^Age x 1.018 [if female] x 1.159 [if black].
- •Where Scr is serum creatinine (mg/dL), ? is 0.7 for females and 0.9 for males, a is –0.329 for females and –0.411 for males, min indicates the minimum of Scr/? or 1, and max indicates the maximum of Scr/? or 1. See protocol appendix VII for details.
- •e) Alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT) and alkaline phosphatase (AP) =2.5 ×ULN (=5 ×ULN in the presence of liver metastasis), and serum total bilirubin =1.5 ×ULN.
- •10) Free T4 and TSH within normal range.
- •11) Archival or newly-obtained representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks must be available.
- •12) Females of childbearing potential must have a negative serum pregnancy test within 7 days of study entry. Patients of childbearing potential who participate in this study must use effective contraceptive methods (e.g., abstinence, intrauterine device, oral or injectable contraceptives, a double barrier method or surgical sterility) to prevent pregnancy starting as soon as the informed consent form is signed and continuing for at least 13 weeks after the last dose of the study medication is administered.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly
排除标准
- •1) Women who are currently pregnant or breast-feeding.
- •2) Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade = 2, or other Grade = 2 not constituting a safety risk based on investigator’s judgment are acceptable.
- •3) Patients who had undergone major surgery, radiation therapy (except for low dose palliative radiotherapy) or treatment with chemotherapy or any investigational agent within 28 days prior to Study day 1.
- •4) Evidence of severe or uncontrolled systemic disease or any concurrent condition (including uncontrolled diabetes mellitus) which in the Investigator’s opinion makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol.
- •5) History of another neoplasm. However, patients with prior history of either non-metastatic non melanoma skin cancers; carcinoma in situ of the cervix; or cancer cured by surgery, small field radiation or chemotherapy =3 years prior to randomisation; or treated patients with early stage and low risk prostate cancer (=pT2 N0 M0, Gleason =6 and Prostate-specific antigen [PSA] =0.5 ng/mL) at study entry will be eligible.
- •6) Prior allogeneic stem cell or solid organ transplantation, or active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. However, patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
- •7) Current use of immunosuppressive medication, EXCEPT for the following:
- •a) Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection);
- •b) Systemic corticosteroids at physiologic doses =10 mg/day of prednisone or equivalent;
- •c) Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- •8) History of idiopathic pulmonary fibrosis.
- •9) Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- •10) Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
- •11) Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
- •12) Active tuberculosis.
- •13) Active infection requiring systemic therapy.
- •14) Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
- •15) Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade = 3).
- •16) Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
不适用
Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable diseaseHLA-A*02-positive patients with advanced clear cell RCC who have progressed during or after previous systemic therapy for advanced disease and have a favourable or intermediate risk after systemic therapy according to the 3-score risk cc prognostic risk category (Motzer 2004).EUCTR2006-006370-25-ATimmatics biotechnologies GmbH72
进行中（未招募）
1 期
Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable diseaseHLA-A*02-positive patients with advanced clear cell RCC who have progressed during or after first-line systemic therapy for advanced disease and have a favourable or intermediate risk after systemic therapy according to the 3-score risk cc prognostic risk category (Motzer 2004).MedDRA version: 9.1 Level: LLT Classification code 10038407 Term: Renal cell cancerEUCTR2006-006370-25-GBimmatics biotechnologies GmbH
进行中（未招募）
不适用
Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable diseaseEUCTR2006-006370-25-BGimmatics biotechnologies GmbH72
进行中（未招募）
不适用
Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable diseaseHLA-A*02-positive patients with advanced clear cell RCC who have progressed during or after first-line systemic therapy for advanced disease and have a favourable or intermediate risk after systemic therapy according to the 3-score risk cc prognostic risk category (Metzer 2004).EUCTR2006-006370-25-HUimmatics biotechnologies GmbH72
进行中（未招募）
1 期
Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease.Estudio de fase 2, aleatorizado, abierto, multicéntrico de IMA901 intradérmico más FEC-GM con o sin pretratamiento de ciclofosfamida en dosis bajas en pacientes con carcinoma de células renales avanzado con enfermedad medible.HLA-A*02 positivos con CCR avanzado que hayan tenido progresión durante o después de terapia sistémica de 1ª línea con riesgo favorable o intermedio después de terapia sistémica, según categoría de pronóstico del riesgo MSKCC de 3 puntuaciones, Metzer 2004. HLA-A*02-positive with advanced RCC who have progressed during or after first-line systemic therapy and have favourable or intermediate risk after systemic therapy according to the 3-score risk cc prognostic risk category, Metzer 2004EUCTR2006-006370-25-ESimmatics biotechnologies GmbH